Opinion|Videos|November 16, 2026

DeLLphi-305 Moves Tarlatamab Into First-Line Maintenance for ES-SCLC

This segment explores the emergence of tarlatamab, a bispecific T-cell engager, in the first-line maintenance setting for extensive-stage small cell lung cancer.

This segment explores the emergence of tarlatamab, a bispecific T-cell engager, in the first-line maintenance setting for extensive-stage small cell lung cancer. Panelists review encouraging early-phase data combining tarlatamab with a PD-L1 inhibitor. They explain why maintenance may be an ideal setting, given lower disease burden and the reality that many patients never receive second-line therapy. They then discuss the design and results of a randomized trial showing a meaningful overall survival advantage for tarlatamab plus a PD-L1 inhibitor, while noting that longer follow-up is still needed. Attention turns to safety, with a practical overview of how cytokine release syndrome presents, how it is graded, and how it is managed with steroids and tocilizumab. Faculty highlight the favorable tolerability seen in the maintenance setting and recent labeling changes that shorten post-infusion monitoring. They also stress the importance of educating patients, caregivers, emergency department staff, and hospitalists to recognize and treat symptoms promptly.


Related to this article